Compare NOG & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOG | ALMR |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Laboratory Analytical Instruments |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2000 | 2026 |
| Metric | NOG | ALMR |
|---|---|---|
| Price | $27.12 | $25.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 5 |
| Target Price | $31.00 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 2.0M | 704.4K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 6.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,475,723,000.00 | N/A |
| Revenue This Year | $6.10 | $59.79 |
| Revenue Next Year | $17.49 | $39.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 11.23 | N/A |
| 52 Week Low | $17.18 | $21.58 |
| 52 Week High | $31.17 | $39.61 |
| Indicator | NOG | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 65.62 | 41.09 |
| Support Level | $26.65 | $23.69 |
| Resistance Level | $27.25 | $29.06 |
| Average True Range (ATR) | 0.75 | 3.14 |
| MACD | 0.34 | -0.75 |
| Stochastic Oscillator | 99.79 | 14.55 |
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.